CervoMed Inc. (CRVO)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Biotechnology (Startups)	9.74M	7.14M
Biotechnology (Startups) Growth	36.29%	-
Total	9.74M	7.14M
Total Growth	36.29%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
United States	9.74M	7.14M
United States Growth	36.29%	-
Total	9.74M	7.14M
Total Growth	36.29%	-

Source: S&P Global Market Intelligence.